Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9552W HIGH $5.50
Volume
317.23 K
Value Traded
599.62 K
Short % Float
15.66%
Days to Cover
6.0
+4.09%Week
-27.59%1 Month
-40.16%3 Month
-47.13%6 Month
-96.58%5 Year
-66.37%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
42.65 M
EPS (TTM)
-1.16
P/E Ratio
-
Ent. Value
23.92 M
Total Shares
42.68 M
Float Shares
37.65 M
Insiders
11.79%
Institutions
31.56%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ANVS Catalyst Timeline
Dated clinical, regulatory and corporate events for Annovis Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Annovis Bio, Inc.
383Total events
21Upcoming
64Tier-1 (high impact)
2019 to 2040Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseBuntanetapCorporate
Annovis announces collaboration with Weave Bio to support planned buntanetap NDA
Alzheimer's diseasesource ↗
▲Enrollment CompleteBuntanetapTrial
Pivotal Phase 3 AD trial fully enrolled
Alzheimer's diseasesource ↗
▲Enrollment CompleteBuntanetapTrial
Pivotal Phase 3 AD trial fully enrolled with 850 patients
Alzheimer's diseasesource ↗
●Enrollment UpdateBuntanetapTrial
PD OLE study enrolled 266 patients toward goal of 500
Parkinson's diseasesource ↗
◆Topline ReadoutBuntanetapClinical Data
Symptomatic readout from Phase 3 trial
early Alzheimer's diseasesource ↗
▲Enrollment CompleteBuntanetapTrial
Full enrollment expected in summer 2026
Alzheimer's diseasesource ↗
▼Equity OfferingCorporate
Pricing of $15.0 million public offering of common stock and warrants
▲Enrollment CompleteBuntanetapTrial
Closed enrollment to new participants after sufficient screening numbers
Alzheimer's diseasesource ↗
▲DSMB ReviewBuntanetapTrial
DSMB positive recommendation on safety at 6 months
Alzheimer's diseasesource ↗
▲Partnership / LicenseBuntanetapCorporate
Partnership with NeuroRPM for AI-powered digital biomarker
Parkinson's diseasesource ↗
▲PublicationBuntanetapPresentation
Peer-reviewed publication of Phase 2/3 AD trial results in Nature NPJ Dementia
Alzheimer's diseasesource ↗
●Poster PresentationBuntanetapPresentation
Two posters presented at AD/PD2026 conference
Parkinson's diseasesource ↗
●Oral PresentationBuntanetapPresentation
CEO presented at Fierce Biotech Week 2026
Alzheimer's diseasesource ↗
▲Patent GrantedBuntanetapIP / Competition
U.S. patent secured for prevention/treatment of neurological injuries from brain infections
neurological injuriessource ↗
●Oral PresentationBuntanetapPresentation
CEO Maria Maccecchini to present on multi-protein model of Alzheimer's disease at Fierce Biotech Week 2026
Alzheimer's diseasesource ↗
▲PublicationBuntanetapPresentation
Publication of Phase 2/3 results in Nature NPJ Dementia
Alzheimer's diseasesource ↗
▲Full ResultsBuntanetapClinical Data
Publication of Phase 2/3 results in Nature NPJ Dementia
Alzheimer's diseasesource ↗
▲FDA Feedback ReceivedBuntanetapFDA Meeting
FDA agreed to integrate safety data from AD and PD trials in NDA
Alzheimer's diseasesource ↗
▲Enrollment UpdateBuntanetapTrial
Parkinson's disease open-label study 28% enrolled
Parkinson's diseasesource ↗
▼Equity OfferingCorporate
Pricing of $10 million underwritten offering of common stock and warrants
▲Patent GrantedBuntanetapIP / Competition
U.S. Patent No. 12,582,632 B2 issued for buntanetap in prevention and treatment of neurological injuries from brain infections
neurological injuries caused by brain infectionssource ↗
◆Enrollment CompleteBuntanetapTrial
Phase 3 AD trial full enrollment expected in summer 2026
Alzheimer's diseasesource ↗
●PublicationBuntanetapPresentation
Publication of historical review article in The Scientist
Alzheimer's diseasesource ↗
▲Enrollment UpdateBuntanetapTrial
70% patients enrolled in pivotal Phase 3 study in early AD
Alzheimer's diseasesource ↗
▲Partnership / LicenseBuntanetapCorporate
Partnership with NeuroRPM to deploy AI-powered digital biomarker technology in PD study
Parkinson's diseasesource ↗
●Enrollment UpdateBuntanetapTrial
ANVS-25002 enrolled 90 out of 500 patients
Parkinson's diseasesource ↗
◆Oral PresentationBuntanetapPresentation
Presentation at AD/PD 2026 on buntanetap in PD patients with MCI or mild dementia
Parkinson's diseasesource ↗
▲DSMB ReviewBuntanetapTrial
DSMB recommends continuation of Phase 3 AD trial without modification
Alzheimer's diseasesource ↗
▲FDA Feedback ReceivedBuntanetapFDA Meeting
FDA indicated may consider accepting combined safety data in future NDA
Alzheimer's diseasesource ↗
▲DSMB ReviewBuntanetapTrial
DSMB positive recommendation on safety at 6 months
early Alzheimer's diseasesource ↗
▲Trial InitiationBuntanetapTrial
Open-label extension study in PD initiated in February 2026
Parkinson's diseasesource ↗
◆Trial InitiationBuntanetapTrial
Open-Label Extension study enrollment begins
Parkinson's diseasesource ↗
◆Type C MeetingBuntanetapFDA Meeting
FDA Type C meeting scheduled to discuss PDD pathway
Parkinson's disease dementiasource ↗
▲FDA Feedback ReceivedBuntanetapFDA Meeting
FDA meeting for new study in PDD; positive recommendation to proceed
Parkinson's disease dementiasource ↗
Past FDA Catalysts and PDUFA Decisions
How ANVS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-17 | buntanetap (investigational oral therapy) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 49%
Micro Cap(rank 322 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buntanetap Small moleculeNCT06709014 | Early Alzheimers Disease | Phase 3 | ACTIVE NOT_RECRUITING | 760 | Jun 1, 2028 | ||||||
| Buntanetap Small moleculeNCT07284784 | Parkinson's Disease (PD) | Phase 2 | RECRUITING | 500 | Nov 1, 2029 | ||||||
| Buntanetap Small moleculeNCT07757204 | Alzheimer's Dementia (AD) | Phase 2 | NOT YET_RECRUITING | 400 | May 1, 2030 | ||||||
| Buntanetap Small moleculeCompletedNCT05357989 | Parkinson's Disease, Idiopathic | Phase 3 | COMPLETED | 523 | Dec 4, 2023 | ||||||
| Buntanetap Small moleculeCompletedNCT05686044 | Alzheimer Disease | Phase 2 | COMPLETED | 351 | Feb 13, 2024 | ||||||
| Posiphen Small moleculeCompletedNCT04524351 | Alzheimer Disease | Phase 1 | COMPLETED | 93 | Jan 31, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANVS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| buntanetap | Alzheimer's disease | Phase 2/3 | 2026-04-28 | 351 patients; 12 weeks; statistically significant, dose-dependent improvements in cognition; 30 mg dose demonstrated a consistent treatment effect across all analyzed patient groupsRead More | Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature PortfolioRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hoffman Michael BDirector | Buy | 2,562 3,291,101 held | $1.75 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANVS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLCcall | 0.1 % (-66.7 %) | 297.79 K | 517.00 | -99.79% ( -249.48 K) |
ANVS Institutional Ownership Trends
ANVS Short Interest
Shares sold short, counted twice a month.
15.66%
Short % of Float
of tradable shares sold short
5.9M
Shares Sold Short
-2.1% vs prior count
6.0 High
Days to Cover
trading days of normal volume to buy every short share back
990.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANVS ranks across every disease it competes in
Competitive Position is a premium feature
See how ANVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANVS News
ANVSAnnovis to Attend the CTAD 2026 with Three Presentations
Annovis Bio, Inc. announced its participation in the CTAD 2026 conference with three presentations focused on its investigational therapy, buntanetap, for Alzheimer's disease. The presentations will discuss the drug's mechanism of action, clinical trial design, and AI applications in drug development. The event is scheduled for November 16-19 in Boston, MA.
Read more →ANVSAnnovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
Annovis Bio has partnered with Weave Bio to prepare for a New Drug Application for its investigational therapy, buntanetap, aimed at treating Alzheimer's disease. The collaboration will enhance the efficiency of NDA document management as the company approaches a key data readout from its Phase 3 trial. Annovis aims to have the NDA ready before the data is released, potentially benefiting many patients awaiting effective treatments.
Read more →ANVSAnnovis to Host Corporate Update Webinar on September 2, 2026
Annovis Bio, Inc. will host a corporate update webinar on September 2, 2026, to discuss its progress in developing the investigational therapy, buntanetap, for neurodegenerative diseases. CEO Maria Maccecchini will present updates on clinical programs and milestones, including the fully enrolled Phase 3 trial for Alzheimer's disease and ongoing discussions for Parkinson's disease dementia. The webinar will also include a live Q&A session.
Read more →ANVSAnnovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Annovis Bio, Inc. has reported significant progress in its clinical trials for Alzheimer's and Parkinson's diseases. The pivotal Phase 3 trial for Alzheimer's is fully enrolled with 850 patients, surpassing initial targets. The company plans to host a corporate update webinar and has outlined upcoming milestones, including a new open-label extension study for Alzheimer's patients. Financial results indicate a net loss, but the company continues to advance its investigational therapy, buntanetap.
Read more →ANVSAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Annovis Bio has achieved full enrollment of 850 patients in its pivotal Phase 3 trial for buntanetap, aimed at treating early Alzheimer's disease. The trial is designed to provide two distinct data readouts: symptomatic effects in Q1 2027 and disease-modifying effects in Q1 2028. The company is preparing for NDA submissions following these readouts, reflecting strong trust from the patient community.
Read more →ANVSAnnovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Annovis Bio has promoted Cheng Fang, Ph.D., to Chief Scientific Officer, a role crucial as the company approaches significant milestones in its Phase 3 clinical trials for the drug candidate, buntanetap. Dr. Fang, who has been with Annovis since 2021, will oversee scientific strategy and research operations for Alzheimer's and Parkinson's disease programs. Her leadership is expected to enhance the company's efforts in clinical development and regulatory interactions.
Read more →ANVS▼ -7.6%on this news
Annovis Bio Regains NYSE Listing Compliance
Annovis Bio has successfully regained compliance with NYSE listing standards after addressing previous non-compliance issues related to market capitalization and stockholders' equity. The company executed corrective actions and provided regular updates to the NYSE, leading to confirmation of compliance ahead of the 18-month deadline. Annovis continues to focus on its clinical programs for Alzheimer's and Parkinson's diseases.
Read more →ANVS▲ +5.2%on this newsshared move
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Annovis Bio, Inc. has announced a public offering of 7,895,000 shares of common stock and accompanying warrants, aiming to raise approximately $15 million. The funds will be used for the clinical development of its investigational therapy, buntanetap, for Alzheimer's and Parkinson's diseases. The offering is expected to close on May 21, 2026, pending customary conditions.
Read more →ANVS▼ -5.4%on this newsshared move
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Annovis Bio, Inc. has announced a proposed public offering of common stock and accompanying warrants to support the clinical development of its lead drug, buntanetap, for neurodegenerative diseases. The offering is subject to market conditions, and details will be filed with the SEC. The net proceeds will be used for continued Phase 3 studies and general corporate purposes.
Read more →ANVSAnnovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Annovis Bio, Inc. reported significant progress in its clinical trials for Alzheimer's and Parkinson's diseases. The Phase 3 trial for Alzheimer's is nearing full enrollment, with a positive safety review. The company anticipates submitting a New Drug Application for its drug, buntanetap, in early 2027. However, financial results show increased losses and reduced cash reserves.
Read more →ANVS▼ -5.8%on this news
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
Annovis Bio's CEO, Maria Maccecchini, will present at Fierce Biotech Week 2026, discussing the multi-protein model of Alzheimer's disease. The presentation will highlight the importance of addressing multiple neurotoxic proteins in disease progression, contrasting with the traditional single-protein focus. Annovis's lead drug, buntanetap, is currently in a pivotal Phase 3 trial.
Read more →ANVSAnnovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Annovis Bio has published positive results from its Phase 2/3 trial of buntanetap for Alzheimer's disease in the journal Nature NPJ Dementia. The study demonstrated significant cognitive improvements in patients with mild to moderate Alzheimer's, alongside a favorable safety profile, including in genetically at-risk individuals. The findings support the ongoing pivotal Phase 3 trial, which is nearing full enrollment.
Read more →ANVSAnnovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Annovis Bio, Inc. has successfully closed a $10 million public offering, extending its cash runway through Q2 2027. This funding will support the Phase 3 trial of its Alzheimer's treatment, buntanetap, which is 75% enrolled. The company anticipates a 6-month data readout in Q1 2027 and has begun preparations for a New Drug Application submission to the FDA. Additionally, an open-label study in Parkinson's disease is underway.
Read more →ANVS▼ -29.6%on this newsshared move
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
Annovis Bio, Inc. has announced a $10 million underwritten offering of common stock and accompanying warrants. The offering consists of 5,263,156 shares priced at $1.90 each, with warrants exercisable at $2.50. Proceeds will support the clinical development of its lead therapy, buntanetap, for Alzheimer's disease. The offering is expected to close around April 10, 2026.
Read more →ANVS▲ +7.5%on this news
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Annovis Bio has secured a U.S. patent for its investigational therapy, buntanetap, aimed at preventing and treating neurological injuries from brain infections. This patent, which extends through 2044, highlights the drug's potential in addressing neurodegenerative diseases like Alzheimer's and Parkinson's. Buntanetap works by reducing the overproduction of neurotoxic proteins triggered by infections, offering a new avenue for treatment.
Read more →ANVS▲ +10.9%on this newsshared move
Annovis Publishes Historical Review of Buntanetap in The Scientist
Annovis Bio, Inc. has published a historical review of its lead drug candidate, buntanetap, in The Scientist. The article outlines the drug's development journey from its origins to its current Phase 3 clinical trials for Alzheimer's and Parkinson's diseases. It emphasizes the scientific rigor and corporate evolution involved in the drug's refinement, showcasing Annovis' commitment to transparency and education.
Read more →ANVS▲ +8.1%on this news
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Annovis Bio announced a partnership with NeuroRPM to deploy an AI platform for monitoring Parkinson’s symptoms in its ongoing buntanetap study. The collaboration integrates digital biomarkers into the ANVS-25002 trial to track disease progression. The open-label study is currently enrolling participants across 25 sites in the United States. It has enrolled 90 out of an estimated 500 patients so far.
Read more →ANVS▲ +12.3%on this newsshared move
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Bio, Inc. reported significant advancements in its clinical development for neurodegenerative diseases, including the initiation of a pivotal Phase 3 trial for Alzheimer's disease and an open-label extension study for Parkinson's disease. The company revealed promising biomarker data suggesting the potential of its investigational drug, buntanetap, to modify disease progression. Financial results showed a net loss but improved cash reserves, allowing operations to continue into mid-2026.
Read more →ANVSAnnovis Announces Two Presentations at the AD/PD™ 2026 International Conference
Annovis Bio, Inc. announced two presentations at the AD/PD™ 2026 International Conference, focusing on its investigational therapy, buntanetap, for neurodegenerative diseases. The presentations will cover clinical data on buntanetap's effects in Parkinson's disease and updates on the ongoing Phase 3 trial for Alzheimer's disease. The conference will take place in Copenhagen from March 17-21, 2026.
Read more →ANVSAnnovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
Annovis Bio has received a positive recommendation from an independent Data and Safety Monitoring Board (DSMB) to continue its pivotal Phase 3 trial of buntanetap for Alzheimer's disease. The DSMB found no safety concerns in the 6-month data, allowing the trial to proceed without changes. The trial is currently 40% complete, with key efficacy readouts expected in early 2027 and 2028.
Read more →About Annovis Bio, Inc.
Headquarters101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
Founded2008
BIOPHARMAWATCH ELITE PLUS
Trade the next ANVS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime